"AI发展特别快，它深入课堂、深入研究一线。小的方面，我天天用豆包、DeepSeek；大的方面，我用 AI去选课题，去更好地做研究。"7月8日，西湖大学校长、2017未来科学大奖获得者施一公在未来科学 大奖十周年庆典上说。 庆典上，西湖大学教授、2023未来科学大奖获得者柴继杰向施一公提问："AI技术如何塑造未来生物学 的研究模式？" 施一公和柴继杰都是著名结构生物学家。近两年，在以AlphaFold（阿尔法折叠）为代表的人工智能系 统问世后，一度有人认为结构生物学家面临"失业"困境。 "不管AI有多大的进步，只要科学家有批判性思维，有好的基础研究训练，就总是可以立于不败之 地。"施一公回答。 施一公认为，AI技术颠覆了传统生物学研究模式，科学家可从三维结构倒推生物学功能，发现新的细 胞生物学现象，新的疾病发生机理，新的遗传学规律，这在以前是不可思议的。AI颠覆了以前从粗到 细、从远到近的研究方式，科学家可以从近往远看，看得非常远，把人类的想象和对科学的追求延展了 几个数量级。 施一公呼吁青年科学家打好科研基本功，更好地用AI；研究人员多合作，跨学科间多交流，从而打开 思维。 "不要忘了，AI实际上可以帮助我 ...

Core Viewpoint - The article emphasizes the importance of supporting and advancing the development of Hubei laboratories in Wuhan to foster technological and industrial innovation, aiming to establish a nationally influential technological innovation hub [1][2]. Group 1: Laboratory Development and Achievements - Eight laboratories in Wuhan have made significant progress in construction and have produced notable scientific achievements, gathering high-end talent and contributing to the development of strategic emerging industries [2]. - The laboratories are encouraged to focus on cutting-edge fields such as aerospace information, enhance technology transfer capabilities, and support the high-quality development of the aerospace information industry in Wuhan [1]. Group 2: Strategic Directions and Recommendations - There is a call for a shift in mindset to adapt to changes in research paradigms and industrial organization, promoting deep integration of technological and industrial innovation through collaboration between academia and industry [3]. - The focus should be on addressing national and local industrial needs, clarifying development directions, and accelerating breakthroughs in key core technologies [3]. Group 3: Talent Attraction and Innovation Environment - Efforts should be made to attract and gather more high-end talent, leveraging high-level innovation platforms and connecting with top domestic and international research institutions and technology companies [3]. - An emphasis is placed on creating a supportive innovation environment that respects knowledge and creativity, ensuring researchers can focus on their work without distractions [4].

Group 1 - The rise of private scientific awards in China has created a social force to encourage scientific innovation, with the "Future Science Prize" being likened to the "Nobel Prize" in China [1] - The "Future Science Prize" has awarded 39 scientists over the past decade, with a single award reaching up to $1 million [1] - The integration of basic, applied, and clinical research in biomedicine is advancing, leading to potential groundbreaking therapies for diseases [1] Group 2 - Experts emphasize the need for more physician-scientists to bridge the gap between basic medical research and clinical application, as their numbers are currently very limited [2] - Research into aging and potential "anti-aging" drugs is progressing, with specific focus on compounds like mTORC1 that may enhance healthy lifespan [2] Group 3 - Controlled nuclear fusion is highlighted as a clean and safe solution to the current energy crisis, with various ignition schemes being explored [4] - The Double-cone ignition scheme (DCI) proposed by Chinese researchers aims to improve the efficiency of laser energy conversion to fusion energy [5] - Achieving room-temperature superconductivity could significantly support controlled nuclear fusion and has broad applications in various fields [5] Group 4 - The intersection of artificial intelligence (AI) and mathematics is being explored to address energy challenges, with AI's high operational costs being a major limitation [6] - AI is expected to have a profound impact on scientific research, particularly in predicting aging mechanisms and enhancing quantum computing [8] Group 5 - Private funding initiatives, such as Tencent's "New Cornerstone Researcher Project," aim to support innovative scientists with substantial financial backing [9] - The focus of these funding projects is on the originality and future potential of scientific research rather than solely on past achievements [9] - There is a call for supporting scientists who are ambitious, young, and willing to explore uncharted territories in science [10]

资料显示，亚盛医药集团是一家立足中国、面向全球的生物医药企业,致力于在肿瘤、乙肝及与衰老相 关的疾病等治疗领域开发创新药物。2019年10月28日,亚盛医药在香港联交所主板挂牌上市,股票代 码:6855.HK。亚盛医药拥有自主构建的蛋白-蛋白相互作用靶向药物设计平台,处于细胞凋亡通路新药研 发的全球前沿。公司已建立拥有9个已进入临床开发阶段的1类小分子新药产品管线,包括抑制Bcl-2、 IAP或MDM2-p53等细胞凋亡通路关键蛋白的抑制剂;新一代针对癌症治疗中出现的激酶突变体的抑制剂 等,为全球唯一在细胞凋亡通路关键蛋白领域均有临床开发品种的创新公司。目前公司正在中国、美 国、澳大利亚及欧洲开展40多项临床试验。用于治疗慢性髓细胞白血病的核心品种奥雷巴替尼(商品名: 耐立克)曾获中国国家药品监督管理局新药审评中心(CDE)纳入优先审评和突破性治疗品种,并已在中国 获批,是公司的首个上市品种。目前,耐立克已被成功纳入《国家基本医疗保险、工伤保险和生育保险药 品目录(2022年)》。该品种还获得了美国FDA快速通道资格、孤儿药资格认定、以及欧盟孤儿药资格认 定。截至目前,公司共有4个在研新药获得16项FDA和1 ...

Core Viewpoint - Fengcai Technology (Shenzhen) Co., Ltd. has successfully listed on the Hong Kong Stock Exchange, with a significant increase in share price on its debut day, indicating strong market interest and investor confidence [1][4]. Summary by Relevant Sections Listing Details - Fengcai Technology's opening share price was HKD 130.8, reflecting an increase of 8.55%. By the end of the trading day, the share price rose to HKD 139.8, marking a total increase of 16.02% [1]. - The total number of shares offered was 18,744,400, with 8,149,800 shares allocated for public offering and 10,594,600 shares for international offering after reallocation [2]. Financial Information - The final offer price was set at HKD 120.5, resulting in total proceeds of HKD 2,258.70 million. After deducting estimated listing expenses of HKD 122.38 million, the net proceeds amounted to HKD 2,136.32 million [4][5]. Use of Proceeds - The funds raised are intended to enhance the company's research and innovation capabilities, expand the product portfolio, develop overseas sales networks, and pursue strategic investments or acquisitions to support long-term growth strategies [5]. Key Investors - Notable cornerstone investors include Taikang Life, Baoyin, 3W Fund, Wind Sabre, Huaxia Fund (Hong Kong), Mega Prime, Sanhua International Singapore, Fourier Capital, Torus, and Intac [5][6]. Company Background - Fengcai Technology specializes in the design and development of BLDC motor drive control chips and has established a strong market position in this sector [5].

今年5月，先达股份在业绩说明会上透露，公司烯草酮产线处于满负荷生产阶段，产品供需紧张，无库 存。根据预计，伴随着烯草酮产品陆续提价，2025年公司利润较同期会有较大增长。 在巩固核心产品优势的同时，先达股份近年来积极转型，停止同质化产品的扩张，大力发展创制产品， 已构建了以喹草酮、吡唑喹草酯、苯丙草酮为核心的创制产品矩阵。其中，吡唑喹草酯为公司第二款创 制除草剂产品，于2024年9月登记获批，2025年正式上市推广销售，目前市场布局已经完成，正在进行 基层市场推广工作。 据介绍，该产品突破传统HPPD类除草剂对籼稻安全性不足的重大难题，填补国际空白。按照规划，公 司吡唑喹草酯将在2025年力争实现500万亩的销售目标，有望带来丰厚利润。 为何业绩大幅增长？先达股份归结为三大原因：一是主打产品烯草酮市场售价上涨，带动公司产品毛利 率的增长；二是创制产品吡唑喹草酯在本年度投放市场，并开展市场推广活动，贡献了新的增长点；三 是公司不断强化成本管控，严格执行降本控费措施，企业运营效率持续提升。 事实上，先达股份业绩复苏迹象此前已经显现。今年一季度，公司录得营收5.43亿元，同比增长 10.78%；净利润2169.3万 ...

上交所官网显示，7月8日，深圳北芯生命科技股份有限公司（以下简称"北芯生命"）科创板IPO对外披露二轮问询回复意见。作为一家选 用科创板第五套上市标准上市的企业，报告期内，北芯生命净利正在逐年减亏。不过，公司核心技术人员离职、销售费用率高于同行、 募投项目能否消化等问题在二轮问询中受到上交所的关注。 核心技术人员离职 报告期内，北芯生命存在核心技术人员离职的情况。 招股书显示，北芯生命是一家专注于心血管疾病精准诊疗创新医疗器械研发、生产和销售的国家高新技术企业，致力于开发为心血管疾 病诊疗带来变革的精准解决方案。截至招股说明书签署日，公司累计向市场推出9个产品，在研产品共有8个，覆盖IVUS系统、FFR系 统、血管通路产品、冲击波球囊治疗系统及电生理解决方案五大产品类别。 研发能力是衡量科创板企业质地的一大因素。2022—2024年，北芯生命研发人员数量持续下滑，分别为151人、136人及109人，且存在核 心技术人员离职的情况。2024年8月，公司核心技术人员李恒伟离职。离职后，公司核心技术人员分别为宋亮、李林、张鹏涛。 上交所在二轮问询中也关注了这一情况，要求公司结合报告期内核心技术人员变化、研发团队的变 ...

Merck & Co (MRK) M&A Announcement July 09, 2025 08:00 AM ET Speaker0 Thank you for standing by. Welcome to the Merck and Company Incorporated Rahway, New Jersey USA Investor Event announcing the acquisition of Verona Pharma Public Limited Company. This call is being recorded. If you have any objections, you may disconnect at this time. I would now like to turn the call over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin. Speaker1 Thank you, Ivy. Good morning, everyone ...

正如一众机构预测，沪指今年首次站上3500点。 下半年开局，A股迎来强势表现，上证指数持续震荡上行。7月9日早盘，上证指数重返3500点，创下年 内新高。尽管午后一度跳水跌破3500点，但今年以来A股也是涨势喜人，涨幅达到4.22%。 近年来，上证指数频繁触及3500点。其中，2024年，随着中国经济进一步复苏和资本市场深化改革，上 证指数多次突破3500点，并于10月一度触及3674.40点高峰。 展望今年下半年，机构观点普遍较为乐观，并认为市场风险偏好已有所抬升，A 股仍将稳步向上。 沪指重返3500点，传媒板块领涨 7月9日，上证指数一度重返3500点，A股午后震荡调整，深证成指翻绿，创业板指涨幅收窄至0.16%。 截至收盘，上证指数微跌0.13%，报3493.05点。 从行业来看，传媒板块领涨，锋尚文化（300860）、中文在线（300364）、华媒控股（000607）、欢瑞 世纪（000892）等个股涨停，百纳千成（300291）、掌阅科技（603533）涨超6%；农林牧渔、商贸零 售、食品饮料等板块跟涨；从概念来看，大唐系指数涨超6%，有研系指数大涨4%，相比之下，此前上 涨的中船系、稀土、GPU ...

每经记者｜朱成祥 每经编辑｜文多 近期，芯片大佬虞仁荣显得格外忙碌。 虞仁荣创办东方理工大学，也是宁波镇海人对尊师重教、崇文向善之风的传承。比如包玉刚、邵逸夫，全国各地都有这两位宁波镇海人的教育捐赠记录。最 巧的是，虞仁荣与"船王"包玉刚一样，不仅是宁波镇海人，还同出生于钟包村。在包玉刚捐建宁波大学的典礼上，虞仁荣就是欢迎行列中的学生代表之一。 这位国内头部CIS（互补金属氧化物半导体图像传感器）厂商豪威集团（SH603501，证券简称此前为韦尔股份）的掌舵人，在资本运作上大步向前。今年， 他旗下另一家公司新恒汇成功登陆A股，并意图推进豪威集团三地上市。 虞仁荣还投入了教育事业，即将开学的宁波东方理工大学便承载着他的教育理想。尽管该校学生每年的学费高达9.60万元，但学校承诺为首届本科生提供等 额奖学金（即学费全免）。 虞仁荣在做客镇海中学时回应了为何创办大学："教育改变了我。如果没有在镇海中学、清华大学的读书经历，我就不是今天的我。" 豪威集团董事长虞仁荣 图片来源：东方理工大学官网文章截图 一所理工大学对产业意味着什么 东方理工大学由宁波市虞仁荣教育基金会举办，由省市共同建设、国家重点支持，是探索高起点、 ...